

Effect of clinical pharmacy specialist intervention on metabolic markers in patients receiving long-acting antipsychotic injection therapy

Samantha Themas, Pharm.D.; Alberto Augsten, Pharm.D., BCPP, DABAT; Claudia Vicencio, LCSW, LMFT; Madeline Camejo, Pharm.D.; Clara Alvarez Villalba, MD
Memorial Regional Hospital, 3501 Johnson Street, Hollywood, FL 33021

Background

❖ Metabolic syndrome is a cluster of symptoms that increases an individual's risk of developing chronic disease states such as type 2 diabetes and atherosclerotic cardiovascular disease¹⁻²

❖ The risk of metabolic syndrome is increased in patients with severe mental illness (SMI) with a prevalence of up to 68%³⁻⁵

❖ Complications from metabolic syndrome is one of the leading causes of death in patients with SMI⁶

❖ Early recognition and management of metabolic symptoms can prevent progression to a state of increased morbidity through the development of type 2 diabetes and cardiovascular disease⁹

❖ American Diabetes Association has released guidelines for the regular screening of metabolic parameters in patients receiving atypical antipsychotic therapy, however these are not consistently followed in current practice^{7,10}

❖ Numerous studies have demonstrated the clinical benefit of pharmacist-physician collaboration in the management of chronic disease states, including metabolic syndrome⁸

Outcomes

Primary: Analyze the effect of clinical pharmacy specialist intervention on metabolic parameters in patients receiving a long-acting antipsychotic injection including:

- ❖ Waist circumference
- ❖ Blood pressure
- ❖ Fasting blood glucose
- ❖ Triglyceride level
- ❖ HDL level

Secondary objectives: frequency of emergency room visits and number of hospitalizations during study period

Methods

❖ Study Design: Prospective quality analysis


❖ Data collection initiated November 29, 2016

❖ Patients receiving long acting injectable antipsychotic therapy at the study location were referred to the pharmacist-run long acting therapy (LAT) clinic

❖ Baseline labs were ordered for all patients and at specified intervals throughout the study base on ADA guidelines

❖ Trends in metabolic parameters were collected and analyzed

LAT Clinic Framework




Clinical Pharmacy Specialist's Role


- ❖ Ensure appropriateness of long acting agent and assist in patient access to medication
- ❖ Assess for medication efficacy and adverse effects using validated scales
- ❖ Provide patient education and set goals to maintain healthy lifestyle choices
- ❖ Establish therapeutic alliance with patient to promote adherence to medication regimen
- ❖ Enhance continuity of care through regular communication with patient and medical team, as well as coordination of all LAT appointments

Results

Overall Change in Percent Body Weight (n=14)



Overall Change in Waist Circumference (inches)



Outcomes

Limited hospitalizations
n = 1 patient

Limited ED visits
n = 1 patient

Improved quality of patient care

Discussion

❖ Total of 14 patients had more than one appointment with clinical pharmacy specialist since beginning of study

❖ Favorable effect on waist circumference observed in short period of time

❖ The investigators plan to continue collecting data over the next several months to assess long term impact of clinical pharmacy specialist services

❖ Interdisciplinary approach to treatment has shown promising results over short amount of time. Longer duration needed to fully evaluate impact of service.

❖ Labs ordered for every patient, only 8 patients had baseline labs drawn – limitation. Addition of on-site laboratory to treatment location will likely improve compliance in very near future.

References

- 1) Grundy SM, et al. Diagnosis and Management of the Metabolic Syndrome. *Circulation*. 2005;112:2735-52.
- 2) Alakkas Z, Alswat KA, Otaibi MA, Althobaiti T, Alzaidi N, Khalek ES, Alfifi A. The prevalence and the clinical characteristics of metabolic syndrome patients admitted to the cardiac care unit. *J Saudi Heart Assoc*. 2016;28:136-143.
- 3) Heald AH, et al. Changes in metabolic parameters in patients with severe mental illness over a 10-year period: A retrospective cohort study. *Australian & New Zealand Journal of Psychiatry*. 2016;1-8.
- 4) Andrade C. Cardiometabolic risks in schizophrenia and directions for intervention, 1: Magnitude and moderators of the problem. *J Clin Psychiatry*. 2016;77(7):844-47.
- 5) Papanastasiou E. The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review. *Ther Adv Psychopharmacol*. 2013;3(1):33-51.
- 6) Shakeri J, Karimi K, Farina V, Golshani S, Alkhanji M. Prevalence of metabolic syndrome in patients with schizophrenia referred to Farabi Hospital, Kermanshah, Iran. *Oman Medical Journal*. 2016;31(4):270-275.
- 7) American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. *Diabetes Care* 2004;27:596-601.
- 8) Hammad EA, Yasein N, Tahaineh L, Albsoul-Younes AM. A randomized controlled trial to assess pharmacist-physician collaborative practice in the management of metabolic syndrome in a university medical clinic in Jordan. *JMPC*. 2011;17(4):295-303.
- 9) Herman WH, et al. Early detection and treatment of type 2 diabetes reduce cardiovascular morbidity and mortality: A simulation of the results of the Anglo-Danish-Dutch Study of intensive treatment in people with screen-detected diabetes in primary care (ADDITION-Europe). *Diabetes Care*. 2015;38(8):1449-1455.
- 10) Mangurian C, Newcomer JW, Modlin C, Schillinger D. Diabetes and cardiovascular care among people with severe mental illness: A literature review. *J Gen Intern Med*. 2016;31(9):1083-91.

Disclosure Panel

Authors of this presentation have the following to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation:

Samantha Themas:	Nothing to disclose
Alberto Augsten:	Nothing to disclose
Claudia Vicencio:	Nothing to disclose
Madeline Camejo:	Nothing to disclose
Clara Alvarez Villalba:	Nothing to disclose